Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px
Document › Details

Biotest AG. (12/11/12). "Press Release: Biotest AG Signs Strategically Significant Agreement to Market Human Albumin in China". Dreieich.

Region Region China
Organisations Organisation Biotest AG
  Group Creat (Group)
  Organisation 2 Wanbang Biopharma (CN)
  Group Fosun (Group)
Product Product albumin, human
Person Person Buttkereit, Monika (Biotest 201308 Head of Investor Relations)
     


- Access to fast growing, high-price Chinese albumin market

- Revenue of EUR 20 to EUR 30 million expected in medium term

- Strong sales and distribution partner Wanbang Biopharma, a Fosun Pharma Group company, as guarantee for success


By signing the long-term distribution agreement Biotest AG emphasized its international growth strategy.

In view of the growing importance of the Chinese market, Biotest has successfully realised the extension of the marketing authorization for human albumin. With regard to rising production capacities, we have looked for a strong sales and distribution partner with whom we can successfully implement our ambitious growth objectives.

In 2011, 180 tonnes of human albumin were sold in China, more than 40% of which were imported. The Chinese pharmaceutical market has reported an annual growth in excess of 20% over the last five years. It is expected that China will be the world's second-largest pharmaceuticals market* by 2014, with sales of around EUR 85 billion.

Wanbang Biopharma is part of the Fosun Pharmaceuticals Group, and is thus one of China's largest pharmaceutical companies. Wanbang Biopharma operates subsidiaries in 28 provinces and employs more than 1,200 marketing and sales staff. With this newly-launched cooperation venture Biotest has secured a position on the Chinese albumin market. Should the Chinese market for plasma products open further, its significance will increase considerably.


About Fosun Pharma

Fosun Pharma is one of the largest Chinese pharmaceutical companies. With a broad pharmaceutical product portfolio, fast growing therapeutic areas such as infectious, liver and mass diseases such as diabetes are served. A strategic partnership with Sinopharma and the most important pharmacists' retail chains ensure an extensive distribution network.

* IMS Report, Datamonitor, MOH year book


Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.


About Biotest

Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of application of clinical immunology, haematology and intensive medicine. In its Plasma Protein portfolio Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest also researches into the development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells. Biotest has more than 1.600 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.


Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Creat (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top